The coronavirus disease (COVID-19), a highly contagious illness, has resulted in one of the worst pandemics in history. COVID-19, unlike other pandemics, has novel transmission mechanisms and produces diverse health-related issues. Severe acute respiratory syndrome coronavirus 2 infection has been associated with thrombocytopenia, neutropenia, and lymphopenia, all of which disrupt the coagulative system and may lead to potentially fatal consequences, including pulmonary embolism. In this review of the oft-documented complications of COVID-19, including venous thromboembolism and pulmonary embolism, coagulative and inflammatory markers, such as ferritin, D-dimer, C-reactive protein, and lactate dehydrogenase have been evinced and the therapeutic options are discussed briefly. It is crucial to detect potential issues early and initiate anticoagulant-based treatments, such as low-molecular-weight heparins and unfractionated heparins to optimize patient outcomes. Therefore, a thorough understanding of COVID-19 pathophysiology and the ability to recognize coagulation abnormalities that are linked to a poor prognosis are necessary to improve patient outcomes.
Key words: Thrombotic complications, D-dimer, patient outcome, SARS-CoV-2
|
